Abstract
When Tadataka Yamada arrived at GlaxoSmithKline (GSK) as the new CEO, following the merger of SmithKline Beecham and Glaxo Wellcome in 1999, he found the company in serious decline in terms of its productivity and innovative capabilities. His first major decision was to initiate a new creative approach to research and development (R&D); restructuring the organization and management of R&D by dividing the company’s 1,900 discovery scientists into six Centres of Excellence in Drug Discovery (CEDDs), each focused on a specific therapeutic area. A seventh CEDD focused on biopharmaceuticals and a “virtual” Centre of Excellence for External Drug Discovery were later established. The impetus for Yamada’s restructuring program was his growing skepticism about the traditional pharmaceutical model of R&D that the large multinational firms had pioneered. In particular, he questioned its reliance on a very centralized and bureaucratic decision-making structure, and was uncomfortable with the artificial distinction between the discovery and development phases of research. The philosophy of the CEDD “hub and spoke” model was to confront GSK’s productivity problem by creating relatively autonomous and geographically diverse R&D units that would replace many of the functions of centralized management systems for the middle stage of R&D (clinical development), where many drugs tend to fail.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Notes
see Coriat, Benjamin., Orsi, Fabienne., and Weinstein, Oliver. (2004) “Does Biotech Reflect a New Science-Based Innovation Regime?” Industry and Innovation 10(3): 231–253.
see Light, Donald W. and Warburton, Rebecca. (2011) “Demythologizing the High Costs of Pharmaceutical Research.” Biosocieties 6: 34–50.
see Di Masi, Joseph A., Hansen, Ronald W., and Grabowski, Henry G. (2005a) “Reply: Extraordinary Claims Require Extraordinary Evidence.” Journal of Health Economics 24(5): 1034–1044,
and Di Masi, Joseph A., Hansen, Ronald W., and Grabowski, Henry G. (2005b). “Reply: Setting the Record Straight on Setting the Record Straight: Response to the Light and Warburton Rejoinder.” Journal of Health Economics 24(5): 1049–1053.
Copyright information
© 2016 James Mittra
About this chapter
Cite this chapter
Mittra, J. (2016). Crisis in the Pharmaceutical Industry and the Promise of New Biology. In: The New Health Bioeconomy. Palgrave Macmillan, New York. https://doi.org/10.1057/9781137430526_2
Download citation
DOI: https://doi.org/10.1057/9781137430526_2
Publisher Name: Palgrave Macmillan, New York
Print ISBN: 978-1-349-57667-8
Online ISBN: 978-1-137-43052-6
eBook Packages: Social SciencesSocial Sciences (R0)